I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| B cell | 9 studies | 19% ± 3% | |
| naive B cell | 8 studies | 19% ± 2% | |
| plasmacytoid dendritic cell | 8 studies | 26% ± 7% | |
| naive thymus-derived CD8-positive, alpha-beta T cell | 6 studies | 17% ± 2% | |
| natural killer cell | 6 studies | 19% ± 3% | |
| memory B cell | 6 studies | 17% ± 1% | |
| endothelial cell | 5 studies | 22% ± 6% | |
| CD16-negative, CD56-bright natural killer cell, human | 5 studies | 21% ± 3% | |
| CD16-positive, CD56-dim natural killer cell, human | 4 studies | 19% ± 2% | |
| CD8-positive, alpha-beta T cell | 4 studies | 23% ± 5% | |
| gamma-delta T cell | 4 studies | 23% ± 14% | |
| hematopoietic precursor cell | 3 studies | 19% ± 4% | |
| T cell | 3 studies | 18% ± 3% | |
| mucosal invariant T cell | 3 studies | 16% ± 0% | |
| pericyte | 3 studies | 17% ± 2% | |
| CD4-positive, alpha-beta T cell | 3 studies | 20% ± 3% | |
| precursor B cell | 3 studies | 24% ± 5% | |
| pro-B cell | 3 studies | 30% ± 6% | |
| fibroblast | 3 studies | 22% ± 3% | |
| epithelial cell | 3 studies | 29% ± 11% | |
| naive thymus-derived CD4-positive, alpha-beta T cell | 3 studies | 17% ± 2% | |
| dendritic cell | 3 studies | 25% ± 6% |
